TY - JOUR
T1 - On-chip integration of enzyme and immunoassays
T2 - Simultaneous measurements of insulin and glucose
AU - Wang, Joseph
AU - Ibáñez, Alfredo
AU - Chatrathi, Madhu Prakash
PY - 2003/7/16
Y1 - 2003/7/16
N2 - A microfluidic device coupling immunological and enzymatic assays within a single microchannel has been developed for simultaneous measurements of insulin and glucose. Such a dual-mode (enzyme/immuno) protocol involves precolumn reactions of insulin and glucose with the enzyme-labeled anti-human insulin and glucose-dehydrogenase/NAD+, respectively, followed by the electrophoretic separation of the free antibody, antibody-antigen complex, and the NADH product of the enzymatic reaction. The separation is followed by a postcolumn reaction of the alkaline-phosphatase tracer with the p-NPP substrate and a downstream amperometric detection of the p-nitrophenol and NADH products. Despite the huge concentration difference [millimolar (glucose) and nanomolar (insulin)] and the use of different assay principles, the new biochip responds independently to the corresponding target analytes, with linear dynamic ranges over their clinically relevant ranges. Complete assays, carried out within less than 4 min, lead to good precision (RSD 0.36%) for the insulin/glucose ratio. The resulting biochip allows simultaneous testing for insulin and glucose to be performed more rapidly, easily, and economically, and hence it holds great promise for improved management of diabetes.
AB - A microfluidic device coupling immunological and enzymatic assays within a single microchannel has been developed for simultaneous measurements of insulin and glucose. Such a dual-mode (enzyme/immuno) protocol involves precolumn reactions of insulin and glucose with the enzyme-labeled anti-human insulin and glucose-dehydrogenase/NAD+, respectively, followed by the electrophoretic separation of the free antibody, antibody-antigen complex, and the NADH product of the enzymatic reaction. The separation is followed by a postcolumn reaction of the alkaline-phosphatase tracer with the p-NPP substrate and a downstream amperometric detection of the p-nitrophenol and NADH products. Despite the huge concentration difference [millimolar (glucose) and nanomolar (insulin)] and the use of different assay principles, the new biochip responds independently to the corresponding target analytes, with linear dynamic ranges over their clinically relevant ranges. Complete assays, carried out within less than 4 min, lead to good precision (RSD 0.36%) for the insulin/glucose ratio. The resulting biochip allows simultaneous testing for insulin and glucose to be performed more rapidly, easily, and economically, and hence it holds great promise for improved management of diabetes.
UR - http://www.scopus.com/inward/record.url?scp=0038713935&partnerID=8YFLogxK
U2 - 10.1021/ja036067e
DO - 10.1021/ja036067e
M3 - Article
C2 - 12848544
AN - SCOPUS:0038713935
SN - 0002-7863
VL - 125
SP - 8444
EP - 8445
JO - Journal of the American Chemical Society
JF - Journal of the American Chemical Society
IS - 28
ER -